NCT04612075Recruiting
The EMINENCE Study - PET/MR Imaging of Head Neck Cancer
Source: ClinicalTrials.gov · Last updated 14 Apr 2026
Brief summary (registry, in English)
Head and neck cancers (HNC) often receive radiotherapy as part of their treatment. However, unacceptable failure rates and severe side effects remain a challenge. The improvements in radiotherapy are closely related to improvements in medical imaging. Functional imaging, where intratumoural characteristics such as tumour oxygenation, metabolism, and blood vessel function can be quantified, offers possibilities to personalize the radiotherapy. In this study we will establish the clinical workflow for PET- and MRI-based radiotherapy in HNC by acquiring images prior to and during radiotherapy to develop new concepts for image-based biologically adaptive radiotherapy, both based on photon-based radiotherapy and also proton therapy, which soon will be available for cancer patients in Norway. The investigators aim to contribute towards further developments of personalised high-precision radiotherapy for HNC patients resulting in improved outcome, reduced side-effects and better quality of life.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 390 (estimated)
- First submitted
- 27 Oct 2020
- Start date
- 12 Jan 2021
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- Norwegian University of Science and Technology
- Diseases
- Head and neck cancer
- NCT number
- NCT04612075
What you commit to
- Study type: Observational
- Planned participants: 390
- From 12 Jan 2021 to the primary completion date, 31 Dec 2025
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- serious comorbidity (including previous or othe cancer) that in the opinion of the investigator would compromise the patient's ability to complete the study of interfere with the evaluation of the study objectives (e.g. poorly controlled diabetes mellitus)
Other
- general contraindications for MRI (pacemaker, aneurysm clips, any form of metal in the body, severe claustrophobia)
- histologically confirmed SCC of same or other origin within the last five years
- patient wants to withdraw for any reason during the study
Who the study is looking for
- willing and able to give full written consent according to the protocol approved by the Regional Ethics Committee
- histologically confirmed squamous cell carcinoma in the head neck region (pharynx, larynx, oral cavity or sinonasal area)
- locally advanced disease without sign of dissemination (T3/T4 and/or N1-3, M0) on diagnostic imaging
- scheduled for definitive radiotherapy with curative intent with or without concomitant chemotherapy
- adequate renal function: Creatinine clearance ≥ 60 ml/minute
- lymph node metastasis from cancer of unknown primary of the upper neck (i.e. level II-III) were PET/CT is negative outside the head-neck region can be considered for inclusion at the discretion of the study investigators.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital of North Norway Coordinator of this site? Confirm its status | Tromsø | Norway | Not yet recruiting |
| St Olavs Hospital, Department of Oncology Coordinator of this site? Confirm its status | Trondheim | Norway | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.